Clinical Trial Update: Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a multi-agent regimen of dinutuximab, GM-CSF, isotretinoin, irinotecan, and temozolomide after intensive therapy in high-risk neurobl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ganglioneuroblastoma
• Neuroblastoma

Drugs mentioned

• ISOTRETINOIN (Isotretinoin)
• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)
• dinutuximab (dinutuximab)
• sargramostim (sargramostim)

Snippet

Sponsor: Children's Oncology Group | Conditions: Ganglioneuroblastoma, Nodular, Neuroblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-14